JGC
CORT icon

J. Goldman & Co’s Corcept Therapeutics CORT Stock Holding History

J. Goldman & Co’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,250
Closed -$510K – 472
2024
Q1 		$510K Buy
+20,250
New +$478K 0.02% 319
2020
Q4 		– Sell
-14,773
Closed -$257K – 394
2020
Q3 		$257K Buy
+14,773
New +$235K 0.02% 277

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

J. Goldman & Co's CORT Position: Q2 2024 in Review

J. Goldman & Co sold out of Corcept Therapeutics (CORT) in Q2 2024, closing a stake of 20,250 shares — an estimated $510K sold.

J. Goldman & Co first reported a position in CORT in Q3 2020 and held it in 2 quarters. The position peaked at $510K in Q1 2024. 286 funds tracked by Wall St. Rank hold CORT as of Q2 2024.

  • J. Goldman & Co reported no remaining Corcept Therapeutics position as of Q2 2024 after selling out during the quarter.
  • J. Goldman & Co sold 20,250 Corcept Therapeutics shares in Q2 2024, an estimated $510K.
  • J. Goldman & Co first reported a position in Corcept Therapeutics in Q3 2020 and held it in 2 quarters.
  • J. Goldman & Co's Corcept Therapeutics position peaked at $510K in Q1 2024.
  • 286 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2024.

Based on J. Goldman & Co's 13F filing for Q2 2024, filed 14 Aug 2024.